| Iain Fraser |
Iain Fraser is currently working as the Senior Vice President-Early Development at Fulcrum Therapeutics, Inc. He previously worked as the Vice President & Clinical Fellow at AlloVir, Inc. He holds a graduate degree from Harvard University, a doctorate degree from the University of Oxford, and an undergraduate degree from the University of Cape Town. |
| Kim Hazen |
Kim Hazen is currently the Chief People Officer at Fulcrum Therapeutics, Inc. Prior to this role, Ms. Hazen held positions as the Executive Director-Human Resources at Aegerion Pharmaceuticals, Inc., the Head-Human Resources at The Broad Institute, Inc., and the Vice President-Human Resources at Warp Drive Bio, Inc. Ms. Hazen holds an MBA degree from Boston University and an undergraduate degree from The State University of New York. |
| Susan O'Connor |
Susan O'Connor is the founder of O'Connor & Associates, which was founded in 2008. She is currently the Chief Human Resources Officer at Beam Therapeutics, Inc. since 2017. Ms. O'Connor has held former positions as Vice President-Human Resources at Johnson & Johnson, Partner at Third Rock Ventures LLC, Chief Human Resources Officer at Blueprint Medicines Corp., Chief Human Resources Officer at Fulcrum Therapeutics, Inc., Chief Human Resources Officer at Relay Therapeutics, Inc., Chief Human Resources Officer at Magenta Therapeutics, Inc., and Chief Human Resources Officer at Celsius Therapeutics, Inc. She received her undergraduate degree from Providence College. |
| Mani Sundararajan |
Mani Sundararajan is currently the Senior Vice President-Technical Operations at Fulcrum Therapeutics, Inc. He has no current former jobs. He received his undergraduate degree from the Institute of Chemical Technology and his graduate degree from the School of Engineering & Applied Science. |
| Mel Hayes |
Mel Hayes is currently the Executive Vice President-Patient Experience at Fulcrum Therapeutics, Inc. Prior to this, he held positions at Genzyme Corp., Bioverativ, Inc., Shire, Inc., Sanofi Ventures, and Baxalta, Inc. His former roles include VP-Rare Blood Disorders & Global Head-Commercial, Vice President-Hemophilia, and Global VP & Head-Global Marketing. Mr. Hayes completed his undergraduate degree at Southern Methodist University and holds an MBA from Columbia Business School. |
| Gregory Tourangeau |
Gregory Tourangeau is currently working as the Chief Accounting Officer & VP-Finance at Fulcrum Therapeutics, Inc. |
| Kathryn Haviland |
Kathryn Haviland is currently the President, Chief Executive Officer & Director at Blueprint Medicines Corp. She is also the Chairman at Fulcrum Therapeutics, Inc. and a Director at Bicara Therapeutics, Inc. Kathryn is a Member of the Harvard Business School Health Industry Alumni Association and the Biopharma Executive Council. In her former positions, Kathryn served as the Executive Director-Commercial Development at PTC Therapeutics, Inc. from 2007 to 2012. She was the Vice President-Rare Diseases at Idera Pharmaceuticals, Inc. from 2014 to 2015, and the Head-Commercial Development at Sarepta Therapeutics, Inc. from 2012 to 2014. Ms. Haviland completed her undergraduate degree at Wesleyan University in 1998. She also holds an MBA from Harvard Business School, which she obtained in 2005. |
| Alan A. Musso |
Alan A. Musso is currently an Independent Director at Aileron Therapeutics, Inc., the Chief Financial Officer & Treasurer at Fulcrum Therapeutics, Inc., and the Chief Financial & Accounting Officer at OS Therapies, Inc. Previously, he held various financial positions at Teva Women's Health, Inc., Lung Therapeutics, Inc., Pfizer Inc., Osiris Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Peloton Therapeutics, Inc., Vascular Genetics, Inc., Cato Research LLC, and Targacept, Inc. He also served as the Chief Financial Officer at ReViral from 2019 to 2022. Musso received his graduate degree from Thunderbird School of Global Management in 2008 and his undergraduate degree from St. Mary's College of California in 1984. |
| Jeffrey W. Jacobs |
Jeffrey W. Jacobs is currently the Chief Scientific Officer at Fulcrum Therapeutics, Inc. Prior to his current position, he was the Chief Scientific Officer at Goldfinch Bio, Inc. and Vice President-Medicinal Chemistry at Ardelyx, Inc. He also held senior positions in development chemistry at Sunesis Pharmaceuticals, Inc. and Affymax, Inc. Additionally, he worked as a Principal at Vicuron Pharmaceuticals LLC and The Damon Runyon Cancer Research Foundation. Jacobs received his undergraduate degree from Gonzaga University and his doctorate from the University of California, Berkeley. |
| Robert J. Gould |
Robert J. Gould is currently the Chairman at HemoShear Therapeutics, Inc. He is also a Director at Spring Arbor University, Turnstone Biologics, Inc., Fulcrum Therapeutics, Inc., Rubedo Life Sciences, Inc., Faeth Therapeutics, Inc., and Khosla Ventures LLC. Additionally, he serves as an Independent Director at Turnstone Biologics Corp. In his former positions, Dr. Gould served as the Secretary & Director at Epizyme, Inc. from 2015 to 2016. He was also a Director at The Broad Institute, Inc. from 2006 to 2010. Furthermore, he held a position as Vice President-Basic Research at Merck Research Laboratories Massachusetts LLC. Dr. Gould obtained his undergraduate degree from Spring Arbor University in 1976. He also holds a doctorate degree from the University of Iowa. |
| Curtis G. Oltmans |
Curtis G. Oltmans is currently an Independent Director at Avenue Therapeutics, Inc. and the Chief Legal Officer at Fulcrum Therapeutics, Inc. He previously worked as the Director at Boys & Girls Club of Trenton & Mercer County. From 1992 to 2005, he served as an Associate General Counsel at Eli Lilly & Co. He also held the position of Secretary, Executive VP & General Counsel at Array BioPharma, Inc. from 2017 to 2019. Prior to that, he worked as an Associate at Shook, Hardy & Bacon LLP from 1989 to 1992. Mr. Oltmans has also held the roles of Vice President & General Counsel at Novo Nordisk, Inc. and Vice President & Litigation Head at Davita Kidney Care, Inc. He completed his undergraduate studies at the University of Nebraska in 1985 and obtained his graduate degree from the University of Nebraska College of Law in 1988. |
| Leslie Leinwand |
Leslie Leinwand was the founder of MyoKardia, Inc. (2012) and Hiberna Corp. (2006), where she held the title of Director. She is also the founder of Gilead Colorado, Inc. Dr. Leinwand's current jobs include serving on the Board of Directors for Global Down Syndrome Foundation, being a Professor at Howard Hughes Medical Institute, Inc., serving as Chief Scientific Officer & Professor at The University of Colorado, and being on the Scientific Advisory Boards for Linda Crnic Institute for Down Syndrome, TARA Biosystems, Inc., Fulcrum Therapeutics, Inc., Edgewise Therapeutics, Inc., and Catalio Capital Management LP as a Venture Partner. Her former job was as a Faculty Member at Albert Einstein College of Medicine, Inc. Dr. Leinwand received her doctorate from Yale University and her undergraduate degree from Cornell University. |
| Patrick Taylor Horn |
Patrick Taylor Horn is currently the Chief Medical Officer at Fulcrum Therapeutics, Inc. He previously held positions as the Medical Director & Head-Clinical Pharmacology at Abbott Laboratories from 2001 to 2006, Vice President-Clinical & Medical Affairs at Dyax Corp. from 2007 to 2010, Chief Medical Officer at Tetraphase Pharmaceuticals, Inc. from 2011 to 2017, Senior VP-Medical & Clinical Development at Orphan Technologies Ltd. in 2018, and Chief Medical Officer at Albireo Pharma, Inc. from 2018 to 2021. He is also currently the Chief Medical Officer at HemoShear Therapeutics, Inc. Dr. Horn obtained a doctorate degree from The University of Chicago and Pritzker School of Medicine, and an undergraduate degree from the University of Illinois. |
| Alexander C. Sapir |
Alexander C. Sapir is currently the Chief Executive Officer & Director at ReViral Ltd., the President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., and an Independent Director at PhaseBio Pharmaceuticals, Inc. Previously, he held positions as the Senior Director-Marketing at Guilford Pharmaceuticals, Inc., the Director at Dova Pharmaceuticals, Inc., and the Executive Vice President-Marketing & Sales at United Therapeutics Corp. Mr. Sapir completed his undergraduate degree at Franklin & Marshall College and holds an MBA from Harvard Business School. |
| James Arthur Geraghty |
James Arthur Geraghty is currently the Chairman at Catalent JNP, Inc., Pieris Pharmaceuticals, Inc., Orchard Therapeutics (Europe) Ltd., OMass Therapeutics Ltd., Bio Ventures for Global Health, Therapeutic Human Polyclonals, Inc., Voyager Therapeutics, Inc., CANbridge Life Sciences Ltd., Fulcrum Therapeutics, Inc., and CANbridge Pharmaceuticals Inc. He previously served as the Chairman, President & Chief Executive Officer at rEVO Biologics, Inc. and the Chairman at Catalent JNP, Inc. from 2015 to 2018. He was also the Chairman at Orchard Therapeutics Plc from 2018 to 2024. Additionally, he held positions as a Director at Idera Pharmaceuticals, Inc., ImmuneXcite, Inc., and bluebird bio, Inc. He was a Director at Aceragen, Inc. from 2013 to 2023 and served as the Senior Vice President at Third Rock Ventures LLC from 2013 to 2016. Prior to that, he was the Senior Vice President-International Development at Genzyme Corp. from 2007 to 2011 and the President at Genzyme Europe BV from 1998 to 2000. He also worked as the Senior VP-Strategy & Business Development at Sanofi SA from 2012 to 2013. Mr. Geraghty holds a graduate degree from the University of Pennsylvania, an undergraduate degree from Georgetown University, and a graduate degree from Yale Law School. |
| Katina Dorton |
Katina Dorton is currently an Independent Director at Mallinckrodt Plc, Director-Research Triangle Chapter at National Association of Corporate Directors (Virginia), Director at Easter Seals UCP North Carolina & Virginia, Inc., Partner at CoRise Co. Llc, Independent Director at Fulcrum Therapeutics, Inc., Independent Director at TScan Therapeutics, Inc., and Director at Sonoma Biotherapeutics, Inc. She has formerly worked as an Independent Director at US Ecology Holdings, Inc. and US Ecology, Inc., Managing Director-Investment Banking at Morgan Stanley, Director at RTP Capital Associates, Inc., Chief Financial Officer at Immatics Biotechnologies GmbH, Chief Financial & Accounting Officer at Avrobio, Inc., Principal Owner at Doric Co. LLC, Chief Financial Officer & Executive Vice President at Repare Therapeutics, Inc., and Chief Financial Officer at NodThera Ltd. She has also worked as an Attorney at Sullivan & Cromwell LLP. She has an undergraduate degree from Duke University, an MBA from George Washington University, and a graduate degree from the University of Virginia School of Law. |
| Sonja L. Banks |
Sonja L. Banks is currently the Chief Executive Officer of The International Dyslexia Association, Inc. She also holds current positions as an Independent Director at Fulcrum Therapeutics, Inc. and Director at Sickle Cell Disease Association of America Michigan. Banks has a graduate degree from Jacksonville State University and an undergraduate degree from The University of Alabama. |
| James J. Collins |
James J. Collins is the founder of Cellicon Biotechnologies, Inc. (founded in 2000), Corvium, Inc. (founded in 2009), Synlogic Operating Co., Inc. (founded in 2014), EnBiotix, Inc. (founded in 2012), Senti Sub I, Inc. (founded in 2016), Synlogic, Inc. (founded in 2017), Sherlock Biosciences, Inc. (founded in 2018), and Cellarity Inc. (founded in 2017). He currently holds the position of Independent Director at Fulcrum Therapeutics, Inc. (since 2017), Independent Director at Orion Biotech Opportunities Corp., Independent Director at Senti Biosciences, Inc. (since 2022), Professor at Harvard University, Professor at Massachusetts Institute of Technology (since 2014), and Member of the National Academy of Sciences, American Academy of Arts & Sciences, National Academy of Engineering, National Academy of Medicine (United States), Excel Medical Ventures LLC (Board of Strategic Advisors), The Broad Institute, Inc., Harvard Mit Health Sciences & Technology, and National Academy of Inventors. He previously held the position of Chief Scientific Officer at Aitia, Inc. (from 2008 to 2012) and Professor at Boston University (from 1990 to 2014). He completed his undergraduate degree at the College of the Holy Cross (Massachusetts) and obtained a doctorate degree from the University of Oxford. |
| R. Alan B. Ezekowitz |
Dr. R. Alan B. Ezekowitz is an Independent Director at Organon & Co., an Advisory Partner at Third Rock Ventures LLC, an Independent Director at Fulcrum Therapeutics, Inc., a Member at American Society of Clinical Investigation and a Venture Partner at CHP Management, Inc. He is on the Board of Directors at Organon & Co., Fulcrum Therapeutics, Inc. and Codman Co., Inc.
Dr. Ezekowitz was previously employed as a Non-Executive Director by Oxagen Ltd., a Principal by Alan Ezekowitz LLC, a Chief Executive Officer & Director by Abide Therapeutics, Inc., a Senior Vice President by Merck Research Laboratories Massachusetts LLC, a Co-Founder by Azanta Danmark A/S, a Director & Chief-Pediatric Services by Partners Healthcare System, Inc., an Associate Professor by Harvard Medical School, a Chairman-Scientific Advisory Board by Anika Therapeutics, Inc., a Director-Scientific Advisory Board by Entomed SA, and a Chairman by Massachusetts General Hospital Cancer Center. He also served on the board at Atopix Therapeutics Ltd. and The Children's Hospital Corp.
He received his graduate degree from the University of Cape Town and a doctorate degree from the University of Oxford. |
